Literature DB >> 11679548

A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum.

C M Tobin1, J Sunderland, L O White, A P MacGowan.   

Abstract

A rapid high-performance liquid chromatography (HPLC) assay for the detection of linezolid in human serum was developed. The method used a Hypersil 5ODS stationary phase. The mobile phase was 1% ortho-phosphoric acid, 30% methanol, 2 g/L heptane sulphonic acid, pH 5. UV absorbance detection was used (lambda(max) 254 nm). Samples were prepared by mixing with acetonitrile and an injection volume of 20 microL was used. The inter- and intra-day assay reproducibility were assessed. Assay linearity, specificity and accuracy were investigated. The detection limit and recovery of linezolid from serum were determined. In addition, the stability of linezolid, stored under a variety of conditions, was assessed. The retention time of linezolid was c. 6.5 min. The intra- and inter-day reproducibility was good and the assay was linear across the therapeutic range. Serum recovery was c. 100% at all concentrations tested. The detection limit was 0.1 mg/L and the assay was accurate. The assay was specific as there was no significant interference with the linezolid peak. Linezolid was demonstrated to be stable. This rapid assay is ideal for busy clinical laboratories with basic HPLC equipment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679548     DOI: 10.1093/jac/48.5.605

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.

Authors:  Wolfgang A Krueger; Bernd Kottler; Bernd E Will; Alexandra Heininger; Heinz Guggenberger; Klaus E Unertl
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.

Authors:  Gabriela Grunder; Yvonne Zysset-Aschmann; Florence Vollenweider; Thomas Maier; Stephan Krähenbühl; Juergen Drewe
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Siu-Wai Cheung; Chi-Chiu Leung; Cheuk-Ming Tam; Chi-Hung Chau; Peter Kin-Ho Wen; Raphael Chiu-Yeung Chan
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

4.  Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.

Authors:  Ronda L Akins; Bradley D Katz; Catherine Monahan; Dylan Alexander
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

5.  Comparison of the pharmacokinetics of linezolid in burn and non-burn rabbits.

Authors:  Jian-Li Ma; Lei Gao; Xiang Li; Wan-Li Chu; Yong-Qiang Feng; Xiao-Qin Wang; Qing-Zhe Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-13       Impact factor: 2.441

6.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

7.  Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.

Authors:  R A Keel; P R Tessier; J L Crandon; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

8.  Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.

Authors:  Pavlos Myrianthefs; Sophia L Markantonis; Konstantinos Vlachos; Maria Anagnostaki; Eleni Boutzouka; Dimitris Panidis; Georgios Baltopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

9.  Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion.

Authors:  Maria Saroglou; Stavros Tryfon; Georgios Ismailos; Ioannis Liapakis; Manolis Tzatzarakis; Aristidis Tsatsakis; Apostolos Papalois; Demosthenes Bouros
Journal:  J Inflamm (Lond)       Date:  2010-05-18       Impact factor: 4.981

10.  Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci.

Authors:  Friedrich Kutscha-Lissberg; Ute Hebler; Gert Muhr; Manfred Köller
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.